December 10, 2014
Chugai Pharmaceutical said on December 9 that the efficacy and safety of ACE910, an anti-factor IXa/X humanized bispecific antibody, were confirmed in a PI study for hemophilia A patients. The study enrolled 18 Japanese hemophilia A patients both with and...read more